Journal article

Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis

Gary R Lichtenstein, Michael A Kamm, Prabhakar Boddu, Natalya Gubergrits, Andrew Lyne, Todd Butler, Kirstin Lees, Raymond E Joseph, William J Sandborn

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | ELSEVIER SCIENCE INC | Published : 2007

Abstract

BACKGROUND & AIMS: SPD476 (MMX mesalamine), a novel, once-daily mesalamine formulation, uses MMX Multi Matrix System (MMX) technology to delay and extend delivery of active drug throughout the colon. We performed a randomized, double-blind, parallel-group, placebo-controlled, multicenter phase III study in patients with mild to moderately active ulcerative colitis. METHODS: Two hundred eighty patients with mild to moderately active ulcerative colitis received MMX mesalamine 2.4 g/day given twice daily (n = 93), 4.8 g/day given once daily (n = 94), or placebo (n = 93) for 8 weeks. The primary end point was the percentage of patients in clinical and endoscopic remission (modified ulcerative co..

View full abstract